SEQENS is one of the world’s leading pharmaceutical solutions and specialty ingredients companies. Headquartered in Lyon, France, SEQENS has revenues of €1.1 billion, 24 industrial sites, 10 R&D centers and 3,200 employees located across 3 continents. The Company has a product portfolio of more than 200 active pharmaceutical ingredients, 500 pharmaceutical intermediates, as well as key specialty ingredients and chemicals.

Concurrent with the acquisition, SEQENS entered a combination with Wavelength Pharmaceuticals, a former SK Capital portfolio company which is also a global manufacturer and developer of active pharmaceutical ingredients.